Clinical Trials Logo
  1. Home
  2. HCC
  3. NCT05825196
  4. Details
NCT05825196 Clinical Trial

Study of Serum Tumor Markers of HBV Associated HCC

HCC Clinical Trial

Official title:
Study of Serum Tumor Markers of HBV Associated HCC

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT05825196
Other study ID # YXLL-KY-2023(026)
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date May 1, 2023
Est. completion date December 31, 2025

Study information
Verified date April 2023
Source Qianfoshan Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In this study, the investigators will detect the expression of four potential HBV-related HCC biomarkers: PGIR,FAM3C,LAMB1 and SDC4 in tumor tissues and peripheral blood, to explore the specific molecular markers for the early diagnosis of HBV-related HCC.

Description:

Paired hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and adjacent liver tissues were selected, and the mRNA and protein expressions of the PGIR,FAM3C,LAMB1 and SDC4 biomarkers in tissues were detected by RT-PCR, western Blot and immunohistochemical analysis. At the same time, healthy subjects were selected as the control group, and mRNA and protein expression levels of the above molecules in blood were detected by RT-PCR and ELISA. At the same time, the correlation between the above biomarkers and the clinical data of patients, such as diagnosis, pathological grading, recurrence, metastasis and survival time was statistically analyzed.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 164
Est. completion date December 31, 2025
Est. primary completion date January 31, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - No local or systemic treatment was performed before surgery. The patients were finally diagnosed with HBV-related HCC by examination and imaging examination, and the clinicopathologic data were complete. Exclusion Criteria: - Patients with benign liver diseases, such as hepatic cysts and hepatic hemangiomas, or have tumors other than HBV-related HCC.

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• tumor tissue and blood tests
In this study, we need to collect an extra tube of blood for routine testing and the tissue after completion of pathological examination.

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Qianfoshan Hospital

Outcome
Type Measure Description Time frame Safety issue
Primary Detection of RNA and protein for diagnosis Detect the content of the RNA and protein in tumor and serum 6 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05458115 - Clinical Study of MRD Recurrence Monitoring After Surgical Resection of Hepatocellular Carcinoma
Not yet recruiting NCT05022628 - Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis Phase 4
Enrolling by invitation NCT02256514 - Open Label Trial of Immunotherapy for Advanced Liver Cancer Phase 2
Not yet recruiting NCT06434480 - SBRT in HCC With Oligoprogression on Atezo-Bev N/A
Completed NCT04542837 - The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma Phase 2
Not yet recruiting NCT05025592 - cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC
Completed NCT04172506 - A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT05840133 - Study of Long Non-coding RNA SNHG15 as a Novel Biomarker in HBV Associated HCC
Not yet recruiting NCT06024252 - Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
Terminated NCT02785874 - Statin With Palliative Therapy for HCC N/A
Not yet recruiting NCT02715492 - Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma. Phase 3
Completed NCT02985034 - Safety Margin Assessment After RFA Using the Registration of Pre-ablation MRI and Post-ablation CT N/A
Not yet recruiting NCT06069947 - SALT for Liver Cirrhosis With HCC N/A
Recruiting NCT05581004 - A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors Phase 1
Suspended NCT02935478 - Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation N/A
Recruiting NCT05592171 - Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC N/A
Completed NCT03176485 - Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors N/A
Recruiting NCT05544253 - Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC Phase 2/Phase 3
Recruiting NCT06184152 - CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
Completed NCT02675920 - A Study of HCC High Risk Group Using Two Surveillance Tools